Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma.

Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ.

Mol Cell Biol. 2005 Jul;25(13):5675-86.

2.

Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice.

Rankin EB, Higgins DF, Walisser JA, Johnson RS, Bradfield CA, Haase VH.

Mol Cell Biol. 2005 Apr;25(8):3163-72.

3.

Coexpression of erythropoietin and erythropoietin receptor in von Hippel-Lindau disease-associated renal cysts and renal cell carcinoma.

Lee YS, Vortmeyer AO, Lubensky IA, Vogel TW, Ikejiri B, Ferlicot S, Benoît G, Giraud S, Oldfield EH, Linehan WM, Teh BT, Richard S, Zhuang Z.

Clin Cancer Res. 2005 Feb 1;11(3):1059-64.

5.

Focus on kidney cancer.

Linehan WM, Zbar B.

Cancer Cell. 2004 Sep;6(3):223-8. Review. No abstract available. Erratum in: Cancer Cell. 2004 Oct;6(4):423.

6.

Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma.

Grabmaier K, A de Weijert MC, Verhaegh GW, Schalken JA, Oosterwijk E.

Oncogene. 2004 Jul 22;23(33):5624-31.

PMID:
15184875
7.

Divergence of renal vascular endothelial growth factor mRNA expression and protein level in post-ischaemic rat kidneys.

Vannay A, Fekete A, Adori C, Tóth T, Losonczy G, László L, Vásárhelyi B, Tulassay T, Szabó A.

Exp Physiol. 2004 Jul;89(4):435-44. Epub 2004 May 6.

8.

Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.

Zimmer M, Doucette D, Siddiqui N, Iliopoulos O.

Mol Cancer Res. 2004 Feb;2(2):89-95.

9.

Patent ductus venosus and dioxin resistance in mice harboring a hypomorphic Arnt allele.

Walisser JA, Bunger MK, Glover E, Harstad EB, Bradfield CA.

J Biol Chem. 2004 Apr 16;279(16):16326-31. Epub 2004 Feb 5.

10.

Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth.

Kondo K, Kim WY, Lechpammer M, Kaelin WG Jr.

PLoS Biol. 2003 Dec;1(3):E83. Epub 2003 Dec 22.

11.

The mammalian basic helix-loop-helix/PAS family of transcriptional regulators.

Kewley RJ, Whitelaw ML, Chapman-Smith A.

Int J Biochem Cell Biol. 2004 Feb;36(2):189-204. Review.

PMID:
14643885
12.

The genetic basis of renal cell carcinoma.

Pavlovich CP, Schmidt LS, Phillips JL.

Urol Clin North Am. 2003 Aug;30(3):437-54, vii. Review.

PMID:
12953747
13.

von Hippel-Lindau disease.

Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, Oldfield EH.

Lancet. 2003 Jun 14;361(9374):2059-67. Review.

PMID:
12814730
14.

Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex.

Maynard MA, Qi H, Chung J, Lee EH, Kondo Y, Hara S, Conaway RC, Conaway JW, Ohh M.

J Biol Chem. 2003 Mar 28;278(13):11032-40. Epub 2003 Jan 21.

15.

Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs.

Wiesener MS, Jürgensen JS, Rosenberger C, Scholze CK, Hörstrup JH, Warnecke C, Mandriota S, Bechmann I, Frei UA, Pugh CW, Ratcliffe PJ, Bachmann S, Maxwell PH, Eckardt KU.

FASEB J. 2003 Feb;17(2):271-3. Epub 2002 Dec 17.

PMID:
12490539
16.

Molecular basis of the VHL hereditary cancer syndrome.

Kaelin WG Jr.

Nat Rev Cancer. 2002 Sep;2(9):673-82. Review.

PMID:
12209156
18.

HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron.

Mandriota SJ, Turner KJ, Davies DR, Murray PG, Morgan NV, Sowter HM, Wykoff CC, Maher ER, Harris AL, Ratcliffe PJ, Maxwell PH.

Cancer Cell. 2002 Jun;1(5):459-68.

19.

Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys.

Rosenberger C, Mandriota S, Jürgensen JS, Wiesener MS, Hörstrup JH, Frei U, Ratcliffe PJ, Maxwell PH, Bachmann S, Eckardt KU.

J Am Soc Nephrol. 2002 Jul;13(7):1721-32.

20.

Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein.

Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG Jr.

Cancer Cell. 2002 Apr;1(3):237-46.

Supplemental Content

Support Center